Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity
Advanced Science · 2025
DOI: 10.1002/advs.202414923 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hao Yan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Chi…. Hauptthemen laut MEDLINE: Crizotinib, Squalene Monooxygenase, Chemical and Drug Induced Liver Injury, Cholesterol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical and Health General Research of Zhejiang Province.
Abstract (Originalsprache)
Metabolic disorders have been identified as one of the causes of drug‐induced liver injury; however, the direct regulatory mechanism regarding this disorder has not yet been clarified. In this study, a single regulatory mechanism of small molecule kinase inhibitors, with crizotinib as the representative drug is elucidated. First, it is discovered that crizotinib induced aberrant lipid metabolism and apoptosis in the liver. A mechanistic study revealed that crizotinib treatment promoted the accumulation of squalene epoxidase (SQLE) by inhibiting autophagosome‐lysosome fusion which blocked the autophagic degradation of SQLE. A maladaptive increase in SQLE led to disturbances in cholesterol and sphingolipid metabolism via an enzymatic activity‐dependent manner. Abnormal cholesterol results in both steatosis and inflammatory infiltration, and disturbances in sphingolipid metabolism promote cell apoptosis by inducing lysosomal membrane permeabilization. The restoration of the level or activity of SQLE ameliorated steatosis and hepatocyte injury. The autophagy activator known as metformin or the SQLE enzymatic inhibitor known as terbinafine has potential clinical use for alleviating crizotinib hepatotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
- Department of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
- School of Medicine, Hangzhou City University, Hangzhou, 310015, China.
ORCID-Profile: Hao Yan, Xiangliang Huang, Yourong Zhou, Yuan Mu, Zhifei Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Förderung
- National Natural Science Foundation of China
- Medical and Health General Research of Zhejiang Province
Zitieren
APA
Yan, H., Huang, X., Zhou, Y., Mu, Y., Zhang, S., Cao, Y., Wu, W., Xu, Z., Chen, X., Zhang, X., Wang, X., Yang, X., Yang, B., He, Q., & Luo, P. (2025). Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity. Advanced Science. https://doi.org/10.1002/advs.202414923
Vancouver
Yan H, Huang X, Zhou Y, Mu Y, Zhang S, Cao Y, et al. Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity. Advanced Science. 2025. doi:10.1002/advs.202414923
BibTeX
@article{Yan2025,
author = {Yan, Hao and Huang, Xiangliang and Zhou, Yourong and Mu, Yuan and Zhang, Shaoyin and Cao, Yashi and Wu, Wentong and Xu, Zhifei and Chen, Xueqin and Zhang, Xiaochen and Wang, Xiaohong and Yang, Xiaochun and Yang, Bo and He, Qiaojun and Luo, Peihua},
title = {Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202414923}
}
EUVIMED